Chemesis International Inc. (OTC: CADMF) (CSE: CSI) (the “Company” or “Chemesis”), announces its intention to enter the recreational and medical cannabis market in Canada. The Company is reviewing possible joint ventures, agreements or acquisitions in distribution, manufacturing, and product development spaces. Chemesis intends on leveraging its assets, brands, and management expertise to gain market share in Canada. Chemesis is presently performing due diligence on fully licensed and operational cannabis companies in Canada.
Canada has significant opportunity in both recreational and medical markets, with the Canadian cannabis market expected to generate up to $7.17 billion CDN in 20191. The Company sees major opportunities in Canada from high-quality manufacturing to brands that have developed a strong presence in the market. Chemesis aims to introduce Canadian consumers its portfolio of brands which includes California Sap, the Company’s flagship brand. California Sap has been recognized in California since 2012, with 25 gold rankings for best CO², best topical, best product, best concentrate, best cartridge, highest terpene and more.
“The Company is looking at multiple opportunities in Canada that will allow us to enter the market and gain a strong presence with minimal regulatory hurdles,” said CEO, Edgar Montero. “Chemesis is only evaluating businesses that have met regulatory and compliance standards. This allows the Company to enter into the market with our assets, and expertise without unnecessary delay. The introduction of California Sap and our other brands will allow Canadians the ability to purchase premium brands, that are extremely accomplished in California. As we continue to execute our business plan, Chemesis will look for acquisitions and partnerships that bring growth and shareholder value.